Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (246)	11/15/2002 4:22:07 PM
From: keokalani'nui	Respond to of 824

Depends on what "it" is. "It" means big deal to me because I need/want to see more support for primo-cabg so I don't feel too out-of-oxygen holding position until 6/30/03. If they show further ckmb correlation with mortality as a matter of science and significance in drug effect on large non-q MI, I'll consider it a success even though primary endpoints are not met. Those endpoints were set long ago. I agree about the market. Say Cardinal trials meet their endpoints, Alexion could get ocinaploned and bicifadined. Wilder